199 related articles for article (PubMed ID: 35854638)
1. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): Results of a Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial.
Pignolo RJ; Baujat G; Hsiao EC; Keen R; Wilson A; Packman J; Strahs AL; Grogan DR; Kaplan FS
J Bone Miner Res; 2022 Oct; 37(10):1891-1902. PubMed ID: 35854638
[TBL] [Abstract][Full Text] [Related]
2. Reduction of New Heterotopic Ossification (HO) in the Open-Label, Phase 3 MOVE Trial of Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP).
Pignolo RJ; Hsiao EC; Al Mukaddam M; Baujat G; Berglund SK; Brown MA; Cheung AM; De Cunto C; Delai P; Haga N; Kannu P; Keen R; Le Quan Sang KH; Mancilla EE; Marino R; Strahs A; Kaplan FS
J Bone Miner Res; 2023 Mar; 38(3):381-394. PubMed ID: 36583535
[TBL] [Abstract][Full Text] [Related]
3. Surgical management of bilateral hip fractures in a patient with fibrodysplasia ossificans progressiva treated with the RAR-γ agonist palovarotene: a case report.
Singh S; Kidane J; Wentworth KL; Motamedi D; Morshed S; Schober AE; Hsiao EC
BMC Musculoskelet Disord; 2020 Apr; 21(1):204. PubMed ID: 32245464
[TBL] [Abstract][Full Text] [Related]
4. Study methodology and insights from the palovarotene clinical development program in fibrodysplasia ossificans progressiva.
Pignolo RJ; Al Mukaddam M; Baujat G; Brown MA; De Cunto C; Hsiao EC; Keen R; Le Quan Sang KH; Grogan DR; Marino R; Strahs AR; Kaplan FS
BMC Med Res Methodol; 2023 Nov; 23(1):269. PubMed ID: 37957586
[TBL] [Abstract][Full Text] [Related]
5. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
6. Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity.
Lees-Shepard JB; Nicholas SE; Stoessel SJ; Devarakonda PM; Schneider MJ; Yamamoto M; Goldhamer DJ
Elife; 2018 Sep; 7():. PubMed ID: 30226468
[TBL] [Abstract][Full Text] [Related]
7. Most Fractures Treated Nonoperatively in Individuals With Fibrodysplasia Ossificans Progressiva Heal With a Paucity of Flareups, Heterotopic Ossification, and Loss of Mobility.
Lindborg CM; Al Mukaddam M; Baujat G; Cho TJ; De Cunto CL; Delai PLR; Eekhoff EMW; Haga N; Hsiao EC; Morhart R; de Ruiter R; Scott C; Seemann P; Szczepanek M; Tabarkiewicz J; Pignolo RJ; Kaplan FS
Clin Orthop Relat Res; 2023 Dec; 481(12):2447-2458. PubMed ID: 37156007
[TBL] [Abstract][Full Text] [Related]
8. Palovarotene: First Approval.
Hoy SM
Drugs; 2022 Apr; 82(6):711-716. PubMed ID: 35384641
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
Wentworth KL; Masharani U; Hsiao EC
Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and mode of action of a combination therapy for heterotopic ossification with a retinoid agonist and an anti-inflammatory agent.
Sinha S; Uchibe K; Usami Y; Pacifici M; Iwamoto M
Bone; 2016 Sep; 90():59-68. PubMed ID: 26891836
[TBL] [Abstract][Full Text] [Related]
11. Imaging assessment of fibrodysplasia ossificans progressiva: Qualitative, quantitative and questionable.
Al Mukaddam M; Rajapakse CS; Pignolo RJ; Kaplan FS; Smith SE
Bone; 2018 Apr; 109():147-152. PubMed ID: 28822792
[TBL] [Abstract][Full Text] [Related]
12. Natural history of fibrodysplasia ossificans progressiva: cross-sectional analysis of annotated baseline phenotypes.
Pignolo RJ; Baujat G; Brown MA; De Cunto C; Di Rocco M; Hsiao EC; Keen R; Al Mukaddam M; Sang KLQ; Wilson A; White B; Grogan DR; Kaplan FS
Orphanet J Rare Dis; 2019 May; 14(1):98. PubMed ID: 31053156
[TBL] [Abstract][Full Text] [Related]
13. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP).
Smilde BJ; Stockklausner C; Keen R; Whittaker A; Bullock AN; von Delft A; van Schoor NM; Yu PB; Eekhoff EMW
BMC Musculoskelet Disord; 2022 Jun; 23(1):519. PubMed ID: 35650602
[TBL] [Abstract][Full Text] [Related]
14. Palovarotene Action Against Heterotopic Ossification Includes a Reduction of Local Participating Activin A-Expressing Cell Populations.
Mundy C; Yao L; Shaughnessy KA; Saunders C; Shore EM; Koyama E; Pacifici M
JBMR Plus; 2023 Dec; 7(12):e10821. PubMed ID: 38130748
[TBL] [Abstract][Full Text] [Related]
15. Cartilage-derived retinoic acid-sensitive protein (CD-RAP): A stage-specific biomarker of heterotopic endochondral ossification (HEO) in fibrodysplasia ossificans progressiva (FOP).
Lindborg CM; Brennan TA; Wang H; Kaplan FS; Pignolo RJ
Bone; 2018 Apr; 109():153-157. PubMed ID: 28963080
[TBL] [Abstract][Full Text] [Related]
16. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial.
Di Rocco M; Forleo-Neto E; Pignolo RJ; Keen R; Orcel P; Funck-Brentano T; Roux C; Kolta S; Madeo A; Bubbear JS; Tabarkiewicz J; Szczepanek M; Bachiller-Corral J; Cheung AM; Dahir KM; Botman E; Raijmakers PG; Al Mukaddam M; Tile L; Portal-Celhay C; Sarkar N; Hou P; Musser BJ; Boyapati A; Mohammadi K; Mellis SJ; Rankin AJ; Economides AN; Trotter DG; Herman GA; O'Meara SJ; DelGizzi R; Weinreich DM; Yancopoulos GD; Eekhoff EMW; Kaplan FS
Nat Med; 2023 Oct; 29(10):2615-2624. PubMed ID: 37770652
[TBL] [Abstract][Full Text] [Related]
17. [18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva.
Eekhoff EMW; Botman E; Coen Netelenbos J; de Graaf P; Bravenboer N; Micha D; Pals G; de Vries TJ; Schoenmaker T; Hoebink M; Lammertsma AA; Raijmakers PGHM
Bone; 2018 Apr; 109():143-146. PubMed ID: 28826841
[TBL] [Abstract][Full Text] [Related]
18. Analog Method for Radiographic Assessment of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva.
Rajapakse CS; Lindborg C; Wang H; Newman BT; Kobe EA; Chang G; Shore EM; Kaplan FS; Pignolo RJ
Acad Radiol; 2017 Mar; 24(3):321-327. PubMed ID: 27989444
[TBL] [Abstract][Full Text] [Related]
19. Response to comment on 'Palovarotene reduces heterotopic ossification in juvenile FOP mice but exhibits pronounced skeletal toxicity'.
Goldhamer DJ; Lees-Shepard JB
Elife; 2019 Jan; 8():. PubMed ID: 30698142
[TBL] [Abstract][Full Text] [Related]
20. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
